Category: St. Jude Medical
Here's a look at some of the top legal news stories for medical device companies this week: Boston Scientific loses $309 million judgment in Mirowski patent war; Ex-Advanced Medical Optics CEO Mazzo indicted in insider trading case; Appeals court denies BD bid to revisit loss to Retractable Technologies; Ackman threatens to sue Allergan again over potential Salix deal; Judge upholds $30M infringement ruling against NuVasive, cancels trademark
Abbott Medical Optics
, AcuFocus Inc.
, Advanced Medical Optics
, Becton Dickinson & Co.
, Boston Scientific
, Mirowski Family Ventures
, NeuroVision Medical Products Inc.
, Pershing Square Capital Management
, Retractable Technologies Inc.
, St. Jude Medical
, Valeant Pharmaceuticals
, Versant Ventures
, Allergan Inc.
Despite Boston Scientific having yet to debut a pacemaker that nestles inside the heart itself, an analyst said the company may be best positioned to capitalize on sales of such devices.
Boston Scientific loses a $309 million judgment in its long-running patent war with Mirowski Family ventures over cardiac pacemaker technology.
UPDATED Sept. 25, 2014, with comment from Boston Scientific.
CE Mark approval expands the company's portfolio of cardiac rhythm devices with MRI compatibility.
St. Jude Medical lands European approval to market its Tendril STS and IsoFlex Optim leads as safe for MRI scanning, adding that the company's just getting started on a larger MRI-safe campaign.
Abiomed unveils new results from an IDE study of its Impella Right Percutaneous heart pump, reporting 73% survival in patients with right ventricular failure.
Abiomed (NSDQ:ABMD) got some Wall Street love today after releasing positive outcomes from a clinical trial of its minimally invasive Impella Right Percutaneous heart pump.
Researchers reported an overall 73% 30-day survival rate in the small study of patients with right ventricular heart failure, according to data Abiomed released during the Transcatheter Cardiovascular Therapeutics conference in Washington D.C.
New data from CardioMEMs CHAMPION clinical trial shows that the company's implanted pulmonary artery pressure monitor helps reduce heart failure hospitalizations without compromising kidney function in patients with renal failure.
St. Jude Medical (NYSE:STJ) subsidiary CardioMEMs touted new study results this week showing that its implanted heart monitor is safe and effective in patients with chronic kidney disease.